PA
HRMY icon

Perceptive Advisors’s Harmony Biosciences HRMY Stock Holding History

Perceptive Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-996,306
Closed -$32.6M – 109
2023
Q3 		$32.6M Buy
996,306
+104,936
+12% +$3.64M 1.09% 29
2023
Q2 		$31.4M Buy
891,370
+791,370
+791% +$27.3M 0.91% 36
2023
Q1 		$3.27M Sell
100,000
-311,804
-76% -$14.2M 0.1% 84
2022
Q4 		$22.7M Hold
411,804
– – 0.64% 40
2022
Q3 		$18.2M Hold
411,804
– – 0.53% 48
2022
Q2 		$20.1M Buy
+411,804
New +$18.5M 0.63% 41
2022
Q1 		– Sell
-239,258
Closed -$10.2M – 142
2021
Q4 		$10.2M Sell
239,258
-252,074
-51% -$10M 0.16% 92
2021
Q3 		$18.8M Hold
491,332
– – 0.27% 70
2021
Q2 		$13.9M Buy
491,332
+179,659
+58% +$5.39M 0.18% 103
2021
Q1 		$10.3M Sell
311,673
-190,949
-38% -$6.7M 0.13% 99
2020
Q4 		$18.2M Buy
502,622
+67,245
+15% +$2.71M 0.2% 90
2020
Q3 		$14.8M Buy
+435,377
New +$15.9M 0.22% 75

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Perceptive Advisors's HRMY Position: Q4 2023 in Review

Perceptive Advisors sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 996,306 shares — an estimated $32.6M sold.

Perceptive Advisors first reported a position in HRMY in Q3 2020 and held it in 12 quarters. The position peaked at $32.6M in Q3 2023. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

  • Perceptive Advisors reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
  • Perceptive Advisors sold 996,306 Harmony Biosciences shares in Q4 2023, an estimated $32.6M.
  • Perceptive Advisors first reported a position in Harmony Biosciences in Q3 2020 and held it in 12 quarters.
  • Perceptive Advisors's Harmony Biosciences position peaked at $32.6M in Q3 2023.
  • 221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Perceptive Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.